Moreover, noncanonical regulatory mechanisms have attracted attention—for instance, the USP14 inhibitor IU1 has been reported to downregulate IDO1 expression and restore T cell–mediated antitumor responses in colorectal cancer models (57). This evidence concerns the gene IDO1 and colorectal cancer.